Christian Baues - Concepedia

Author

Christian Baues

Also Known As

B. Nast-Kolb, C Baues, C. Baues, C.M. Baues, CHRISTIAN BAUES, Christian Baues, Christian M. Baues, Nathalie L. Albert, Oliver Blanck

195

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University Hospital Cologne University of Cologne University Hospital Münster Heinrich Heine University Düsseldorf Düsseldorf University Hospital

About

Christian Baues is an author at University Hospital Cologne specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	890
2	Health Sciences	5	5	644
3	Immunology	3	3	208
4	Cellular Therapies	1	1	37
5	Orthopaedics	1	1	23

Christian Baues

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group Peter Borchmann, Helen Goergen, Carsten Kobe, The Lancet Positron Emission TomographyAdvanced-stage HodgkinLymphoid NeoplasiaSurgical OncologyOncologic Imaging	2017	372
Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group Michael Fuchs, Helen Goergen, Carsten Kobe, Journal of Clinical Oncology	2019	217
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma Paul J. Bröckelmann, Helen Goergen, Ulrich Keller, JAMA Oncology	2020	162
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial Peter Borchmann, Annette Plütschow, Carsten Kobe, The Lancet Oncology Lymphoid NeoplasiaRadiation TherapyPet-guided OmissionMedicineGhsg Hd17	2021	153
Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma Sebastian Theurich, Sacha I. Rothschild, Michael Hoffmann, Cancer Immunology Research ImmunologyImmunoeditingPathologyDermatologyImmunotherapy	2016	144
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group Peter Borchmann, Heinz Haverkamp, Andreas Lohri, The Lancet Oncology Lymphoid NeoplasiaProgression-free SurvivalOncologyRandomised Phase 3Pathology	2017	89
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, The Lancet	2024	87
Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma Jasmin Mettler, Horst Müller, Conrad‐Amadeus Voltin, Journal of Nuclear Medicine	2018	82
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial Paul J. Bröckelmann, Ina Bühnen, Karolin Trautmann‐Grill, Journal of Clinical Oncology	2022	78
Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition Maike Trommer, Sin Yuin Yeo, Thorsten Persigehl, Frontiers in Pharmacology	2019	77

Page 1